From Wrist to Wallet: Wearables Become Wellness Payments

State of play

The wearable is becoming an insurance benefit line. In South Africa, Discovery Vitality will let members fully fund an Apple Watch through Active Rewards, or an Oura Ring 4 through a new Sleep Rewards program, by achieving goals over 24 months — the Oura route covering up to R9,997 with a R999 activation fee and including a 24-month Oura Membership. In the US, John Hancock’s Vitality Plus lets life-insurance members earn an Apple Watch — now spanning Series 11 and Ultra 3 — for as little as $25 up front, with monthly payments falling from $15.50 at zero activity points to $0.00 at 500 points, earned at 20-30 points per workout. Whoop completes the clinical loop: its HealthEx partnership syncs electronic health records with continuous biometric data, grounding coaching in medical history. The adoption base justifies the institutional attention — 46% of 8,000 US adults polled own a wearable, and 59% of owners have discussed biometric data with a healthcare provider. Oura, meanwhile, closed a $900M+ Series E led by Fidelity at an $11 billion valuation, with 5.5M+ rings sold and 2025 revenue above $1 billion.

Why it matters

When a life insurer subsidizes a device to zero, the wearable stops being a consumer gadget and becomes an actuarial instrument: the insurer is buying behavioral data and, it expects, lower claims. That flips the category’s funding logic — device economics now ride on payer budgets, which are larger and stickier than retail. For the wider wellness economy, the same mechanism builds the rails for activity-based payments: funded devices, rewards points and premium discounts are each a short step from paying directly for verified exercise. Whoop’s EHR integration shows where the data ends up, and Oura’s valuation shows what the market thinks the data is worth. The open question is proof: insurers will scale device funding from marketing budgets to claims budgets only when device-funded members demonstrably cost less, so the outcome studies now running quietly inside vitality programs are the numbers that decide this trend’s ceiling.

Momentum call: rising, dated 2 November 2026 — insurer funding programs, clinical data integrations and late-stage valuations are all compounding.

What to watch

• Whether US health insurers copy full-funding device models beyond life-insurance vitality programs.
• Governance of EHR-linked biometric data as the clinical loop tightens.
• Whether device-funded members show measurably lower claims — the evidence that unlocks bigger budgets.
• Whether Oura’s postponed IPO reopens a public-market window for connected health.